See also: Related OurFood News
Infant nutrition consists of two phases:
1. Diet solely of breast milk or breast milk substitutes (first 4-6 months)
2. Diet with breast milk or breast milk substitutes supplemented with weaning food (at the earliest from 5 months, at the latest from 7 months.
If a mother is unable to or does not breastfeed, breast milk substitutes can be given to healthy, full-term infants:
a - Infant formula can replace breast milk from birth onwards and like breast milk is suitable as the sole source of food for the first four to six months. After that infant formula plus weaning food can be given throughout the first year of life. In Germany and in the European Union there are four types of infant formula:
- based on cow's milk protein with lactose as the sole carbohydrate.
- based on cow's milk protein with other carbohydrates besides lactose
- based on soy bean protein isolate (N.B.: this food is only lactose-free in Germany)
- based on partially hydrolysed (cleaved) protein (name HA). This initial food is intended for non-breast fed infants from families with a history of allergies.
b - Follow-on formula can replace breast milk at the earliest from the fifth month onwards. It is not suitable from birth onwards as it is not adapted to the needs of the very young infant. There is no compelling reason to switch from infant formula to follow-on formula.
c - Weaning food is the name for all dietary foods intended specifically for infants (and small children) which should supplement the diet with breast milk or breast substitute products at the earliest from the 5th month and at the latest from the 7th month onwards. It is recommended that weaning food be selected which corresponds to the Ernährungsplan des Forschungsinstituts für Kinderernährung in Dortmund (Nutrition Plan of the Research Institute for Children's Nutrition in Dortmund) and to use them in the stipulated sequence.
Both for infant bottle formula and weaning food products there are especially stiff statutory provisions concerning the composition, the use of additives (colouring agents, flavourings, preservatives are banned), the bacteriological requirements and the limit values for residues and contaminants which are uniform throughout the European Union 
The UK Food Standards Agency promulgates the following advices on how to feed a
baby. According to the advice of the Agency
breastfeeding is best for babies. It should continue exclusive breastfeeding for
six months, the longer the better. Continue to give breast milk or formula milk
until it is at least a year old. A change to follow-on milk isn't necessary at
Infant formula is the only alternative to breast
milk. Cows' milk is not suitable as a drink until a baby is a year old because
it contains too much salt and protein, and not enough iron and other nutrients,
to meet your baby's needs. The amount of
solid foods may be gradually increased, beginning from the sixth month so that by twelve months, solid foods become the main part of your baby's diet, with
breast or formula milk making up the balance. FSA says that commercial baby foods
can be useful but should not replace family foods altogether. It is cheaper than
buying baby foods, you'll know what the ingredients are, and your baby will get
used to eating like the rest of the family. The FSA recommends to
make sure to give two servings a day of pulses (such as red lentils, beans or
chickpeas), or tofu to make sure they get all the energy and nutrients they
need. The vitamin C in fruit and vegetables helps the absorption of iron,
fruit and vegetables at mealtimes should therefore not be forgotten at baby's meal. Babies up to 6 months old should have less than 1g salt a day.
From 7 months to a year old they should have a maximum of 1g salt a day. Avoid adding sugar to the food or drinks you give your baby.
If you give your baby stewed sour fruit, such as rhubarb, you could sweeten it
with mashed banana, breast or formula milk. Honey can contain
a type of bacteria that may produce infant botulism. Honey should therefore be
avoided for babies under one year, after that age the intestine matures and the
bacteria can't grow. Because
of possible allergies babies under six years old should not be fed with: This includes bread, wheat
flour, breakfast cereals and rusks. This includes
peanuts, peanut butter and other nut spreads. Peanuts can be given from six
months old onwards, if you always crush or flake them. might be prescribed a GP if a
baby has an allergy to cows' milk. They
should only be fed on the advice a GP or health visitor. Babies who are allergic
to cows' milk may also be allergic to soya. are not suitable
for babies, and have not been approved for use in Europe. Since the levels of
lactose are similar in both milks, formulas derived from goats' milk are also
unsuitable for babies that are lactose-intolerant. Pasteurised goats' and
sheep's milk can be used once a baby is a year old. Start using full-fat milks in
cooked foods, and full-fat milk products, such as yoghurt after the age of six
month. The FSA says that water is the best alternative drink to milk,
but fully breastfed babies don't need any water until they start eating solid
food. For babies under six months old, take water from the mains tap in the
kitchen and boil it. FSA comments that Fruit juices, such as orange juice,
are a good source of vitamin C, particularly for vegetarian diet or breastfed
babies, however fruit juice should not be given to babies under six month.
However, vitamin C might help our bodies absorb iron from a meal, so you may be
advised to give diluted fruit juice with your child's meals after six months, In
this case, give very dilute juice (one part juice with ten parts cooled, boiled
water) in a feeding cup and at mealtimes only.
According to Kiefte-de Jong et al. 2012, children born in Rotterdam, the Netherlands, who ate fish for the first time between the ages of 6 and 12 months but had no dietary fish intake at 14 months were less likely to have asthma symptoms, such as wheezing and shortness of breath, as preschoolers. The protective effect of fish was not seen when they first ate fish when they were younger than 6 months or eating no fish in their first year of life. Diets high in fish, vegetables, and fruit have been found to protect pregnant women and school-aged children from asthma.
Introducing fish in diet of low-aged children protects of asthma 
The authors concluded that early life exposure to n-3 polyunsaturated fatty acids (n-3 PUFA) protects against developing asthma, and there is a specific window of opportunity between the age of 6 and 12 months which causes the protection effect of fish against asthma. The study was part of the Generation R Study, a multiethnic prospective birth cohort in Rotterdam.
For US laws, Regulations, and Guidance please refer to the US FDA/CFSAN Infant Formula Homepage under Program Area: Infant Formula http://www.cfsan.fda.gov/ 
The new regulations of the Commission Directive 2006/141/EC amending Directive
1999/21/EC on baby food is focused on the nutritional value of the formula to
satisfy the nutritional requirements of the infant.
FSA says the rules will help parents and carers to clearly tell the difference
between infant formula, which can be used for the first six months, and
follow-on formula, which is only to be used after six months.
It also hopes to make sure labelling and advertising is in line with the
principles laid out in the European code, on infant formula and follow-on
formula and amending Directive 1999/21/EC.
Baby Milk Action say advertisements for formula are putting mothers off
breastfeeding, and campaign for a complete ban.
Baby Milk Action is a non-profit organisation which aims to save lives and to
end the avoidable suffering caused by inappropriate infant feeding. 
A marketing code was introduced in 1981 to regulate the marketing of
breastmilk substitutes. Companies continue to violate its provisions.
The Infant and Dietetic Foods Association (IDFA) wants to delay by two years the regulation to come into force applying for a judicial review . 
According to a notice of FSA the UK High Court has ruled that manufacturers
may continue to produce (and retailers may continue to sell) infant and
follow-on formula bearing the current labels until 1 January 2010. After this
time, they will have to ensure that products are labelled in accordance with
the new labelling rules in the 2007 regulations. The judgement does not affect
the rules relating to advertising of infant and follow-on formula, which apply
The implementation of new European legislation on infant and follow-on
formula. infant and follow-on formula legislation was announced by the
Department of Health and the Food Standards Agency in November. It is designed
to introduce stricter controls on labelling and advertising of all types of
formulae to ensure that breastfeeding is not undermined by the marketing and
promotion of such products.   
The Codex in its ALINORM 05/28/26(2004) - 06/29/26(2005) and 07/30/26
Rev(2006) lays down the standard for the composition of infant formulas.
Highlights of this standard are:
Definition of infant formula
Infant formula means a breast-milk substitute specially manufactured to satisfy, by itself, the nutritional requirements of infants during the first months of life up to the introduction of appropriate complementary feeding. Infant formula is so processed by physical means only and so packaged as to prevent spoilage and contamination under all normal conditions of handling, storage and distribution in the country where the product is sold. The term infant means a person not more than 12 months of age.
Infant formula is a product based on milk of cows or other animals and/or other ingredients which have been proven to be suitable for infant feeding. The nutritional safety and adequacy of infant formula shall be scientifically demonstrated to support growth and development of infants.
All ingredients and food additives used shall be gluten-free.
Essential and semi-essential amino acids in breast milk
For an equal energy value the formula must contain an available quantity of each essential and semi-essential amino acid at least equal to that contained in the reference protein (breast-milk as defined in Annex 1.
Infant formula prepared ready for consumption in accordance with instructions of the manufacturer shall contain per 100 ml not less than 60 kcal (250 kJ) and not more than 70 kcal (295 kJ) of energy.
Isolated amino acids may be added to Infant Formula only to improve its nutritional value for infants. Essential and semi-essential amino acids may be added to improve protein quality, only in amounts necessary for that purpose. Only L-forms of amino acids shall be used.
Nutrients of infant formula
Nutrients in 100 g/ml are given in table 3.1.3 of the Standard.
In addition to the compositional requirements listed under 3.1, other ingredients may be added in order to provide substances ordinarily found in human milk and to ensure that the formulation is suitable as the sole source of nutrition for the infant. Only L(+) producing lactic acid cultures may be used.
Vitamin Compounds and Mineral Salts
Vitamins and minerals added should be selected from the Advisory Lists of Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children (CAC/GL 10-1979). 
The product and its components shall not contain commercially hydrogenated oils and fats and shall not have been treated by ionizing radiation.
In this standard part 4. the permitted food additives are grouped as thickening agents, emulsifiers, pH adjusting Agents, Antioxidants and packaging gas (propellants).
The standard sets a maximum level of lead of 0.02 mg/kg (in the ready-to-use product)
The product should comply with the appropriate sections of the following codes:
Fill of Container
- Recommended International Code of Practice - General Principles of Food Hygiene (CAC/RCP 1 1969, Rev. 3 - 1997), 
- Recommended International Code of Hygienic Practice for Foods for Infants and Children (CAC/RCP 21-1979). 
- Principles for the Establishment and Application of Microbiological Criteria for Foods (CAC/GL 21-1997) 
In the case of products in ready-to-eat form, the fill of container shall be:
Labelling Labelling should comply with Guideline:
- Not less than 80% v/v for products weighing less than 150 g (5 oz.)
- Not less than 85% v/v for products in the weight range 150-250 g (5-8 oz.)
- Not less than 90% v/v for products weighing more than 250 g (8 oz.)
Labelling should contain:
The name of the product shall be either "Infant Formula" or any appropriate designation indicating the true nature of the product, in accordance with national usage.
- Codex General Standard for the Labelling of Prepacked Foods (CODEX STAN 1-1985 (Rev. 1-1991), 
- Codex Guidelines on Nutrition Labelling (CAC/GL 2-1985 (Rev.1-1993) 
- Guidelines for Use of Nutrition and Health Claims 
The sources of protein in the product shall be clearly shown on the label.
If cow's milk is the only source of protein, the product may be labelled "Infant Formula Based on Cow's Milk".
A product which contains neither milk or any milk derivative shall be labelled "contains no milk or milk products" or an equivalent phrase.
Products containing not less than 0.5 mg Iron (Fe)/ 100 kilocalories shall be labelled "Infant Formula with added Iron".
Or Products containing less than 0.5 mg Iron (Fe)/ 100 kcal shall be labelled with a statement to the effect that when the product is given to infants over the age of four months, their total iron requirements must be met from other additional sources. 
Lozoff and colleagues 2003 suggest that unsupplemented infants responded less
positively to the physical and social environment and blame it to iron deficiency
on the developing brain. The authors recommend iron supplementation in the first
year of life. Usha Ramakrishnan and colleagues 2004 in a meta-analyses of randomized controlled
intervention trials assessing the effects of vitamin A, iron, and
multimicronutrient interventions on the growth of children under 18 years old
found that suplementation of vitamin A or iron alone did not improve child
growth. Multimicronutrient, however, improved children growth.
Emorn Wasantwisut and colleagues 2006 found in a study that iron
supplementation improved hemoglobin, iron status, and ponderal growth, whereas
zinc supplementation improved zinc status. The authors concluded that for
infants, combined iron and zinc supplementation is preferable to iron or zinc
A study of Khulan et al. 2012 supports the hypothesis that undernutrition during gestation and infancy predisposes to ill health in later life. The researchers suggest that micronutrient supplementation might be a cause of methylation of foetal genes which control the immune system.
Such changes were found by the authors in the DNA of cord blood and in a 9 months after birth. The authors stress that children born in Gambia during the wet season were at higher risk of infections than children born in the dry season. During the wet season less food is available as compared to the dry season. The reduced supply of micronutrients during the wet season may weaken the immune system due to a methylation of genes linked to disease resistance.
The link of nutrition and methylation of genes during and after gestation was demonstrated by supplementation of micronutrients of pregnants compared to a group without supplementation. Of micronutrients. The authors suggest that periconceptional nutrition in humans is an important determinant of newborn whole genome methylation patterns but may also influence postnatal development.
Intrauterine exposures mediated by maternal diet may also affect risk of cardiovascular disease, obesity, and type 2 diabetes. Cooper et at 2012 studied the DNA methylation at 12 differentially methylated regions (DMRs) was analysed in cord blood samples of pre- and periconceptional micronutrient supplementation which included folate, zinc, and vitamins A, B, C, and D. 
Trials investigating the effect of maternal supplementation of protein-energy, multiple-micronutrient and Ca on CVD risk in offspring were assessed by Hawkesworth 2009.
Lower systolic blood pressure at 2 years of age in Nepal were reported. However no blood pressure reduction was found in the protein-energy trial in Guatemala trial, where only a reduction of fasting glucose and body composition was reported. No association between supplementation and CVD.
In The Gambia no association has been found between prenatal protein-energy supplementation and markers of CVD risk including body composition, blood pressure and fasting glucose and insulin in childhood and adolescence. 
The author concluded that four trials presented little evidence of an effect of maternal Ca supplementation on offspring blood pressure has been demonstrated in four trials, except reduced risk of high systolic blood pressure in one trial.
Zinc is, after iron, the most important trace elements in the body,being related
to a healthy immune system, influence memory, muscle strength and endurance in
According to Thomas Tompkins and colleagues compared the bioavailability of
zinc gluconate and zinc from yeasts in two studies presented in 2007.
The first study found zinc yeast to have significantly less loss in the
faeces, accounting for a gain in net zinc balance, while, in comparison, zinc gluconate supplementation resulted in net loss of zinc through the faeces. 
In the second study Tomkins and colleagues wrote that zinc-enriched yeast was 3.7
times more bioavailable than the zinc gluconate and that copper-enriched yeast
was 1.4 times more bioavailable than the Cu gluconate. Lallemand Health
Ingredients is waiting for the approval from EFSA for the mineral enriched
yeast supplement.  
Dietary intake was not significantly correlated with hemoglobin concentrations
according to a study by Inger Öhlund and colleagues. The authors found in
this study that the consumption of meat products had a positive effect on
serum ferritin concentrations and mean corpuscular volume in boys.
In healthy, well-nourished children with a low prevalence of iron deficiency, the
mother's but not the father's hemoglobin was significantly associated with that
of her child, but the authors could not explain its reason. 
Lozoff and colleagues 2008 assessed the dose-response relationships between
severity of iron deficiency (ID) and infant social-emotional behaviour. The
authors found a linear effects of poorer iron status for shyness (increasing,
maternal rating), orientation-engagement, and soothability (decreasing, examiner ratings).
The authors stress that iron deficiency without anemia is not detected by common
screening procedures and is more widespread than the other form, and social-emotional behaviour can profoundly influence the care-giving environment,
with repercussions for overall development. 
Infant formulas are fortified in USA with 12 mg/L of iron to prevent
iron-deficiency anaemia whereas Europe generally uses a lower amount; in the
UK, the limit for iron in cows milk based infant formula is 1.5mg/100 kcal and
2,0 mg/100 kCal. 
According to Betsy Lozoff and colleagues iron-fortified baby formula may pose
a developmental risk to children who do not need iron supplementation. The
authors found that ten years after receiving formula containing 12 mg/L of iron
as infants, children had lower scores across a battery of developmental tests
compared with children given formula containing 2.3 mg/L of iron.
The authors, however call for more studies on this subject before any change is warranted.
According to Shafir and colleagues 2008 poorer motor function in iron deficient
infants with and without anemia were found, Whereas non anemic iron deficiency
were classified by the authors as particularly concerning, since it is not
detected by common screening procedures and is more widespread than the anemic
List of Ingredients
A complete list of ingredients shall be declared on the label in descending order of proportion.
Declaration of Nutritive Value
It should contain:
- The amount of energy, expressed in kilocalories (kcal) and/or kilojoules (kJ), and the number of grammes of protein, carbohydrate and fat per 100 grammes or per 100 millilitres of the food as sold as well as per 100 millilitres of the food ready for use, when prepared according to the instructions on the label.
- The total quantity of each vitamin, mineral, choline as listed in paragraph 3.1.2 and any other ingredient as listed in paragraph 3.2 of this Standard per 100 grammes or per 100 millilitres of the food as sold as well as per 100 millilitres of the food ready for use, when prepared according to the instructions on the label.
- In addition, the declaration of nutrients in a) and b) per 100 kilocalories (or per 100 kilojoules) is permitted.
Basic informations of the Codex guidelines for infant formulas
- The date of minimum durability (preceded by the words "best before") and storage instructions.
- Information for use.
- Labels should not discourage breastfeeding.
- Label should contain the statement "Breastmilk is the best food for your baby" or a similar statement as to the superiority of breastfeeding or breastmilk.
- Label should contain a statement that the product should only be used on advice of a independent health worker as to the need for its use and the proper method of use.
- The label shall have no pictures of infants and women nor any other picture or text which idealizes the use of infant formula. The terms "humanized", "maternalized" or other similar terms shall not be used.
- Information shall appear on the label to the effect that infants should receive supplemental foods in addition to the formula, from an age that is appropriate for their specific growth and development needs, as advised by an independent health worker, and in any case from the age over six months.
- The products shall be labelled in such a way as to avoid any risk of confusion between infant formula, follow-up formula, and formula for special medical purposes.
- No nutrition and health claims shall be made regarding the dietary properties of the product.
The Codex guidelines for infant formulas was based on the recommendations on the compositional requirements for a global infant formula standard from Koletzko et al (2005) from the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) which had formed an International Expert Group (IEG) collecting data for the guidelines. 
One important conclusion of the IEG was that infant formulae should only contain components in such amounts that serve a nutritional purpose or provide another benefit. The inclusion of unnecessary components, or unnecessary amounts of components, may put a burden on metabolic and other physiologic functions of the infant. 
Carlo Agostoni and Magnus Domellöf in an editoral in 2005 presented a list of recommended concentrations of nutrients in infant formulae 1977-2005 which helped to fill a data gap. 
Reduction of severity of diarrhoea with fermented infant formulae 
Carlo Agostini and colleagues in an analysis found only limited published data on the effects of fermented infant and follow-up formulae. In these products the lactic acid producing bacteria are heat inactivated after the fermentation. Only 2 studies mentioned that some fermented infant formulae may reduce the occurrence or severity of infectious diarrhoea in infants.
The authors recommend further studies on the effects of fermented infant formulae on infectious diarrhoea and other relevant outcomes Available data do not allow general conclusion on this matter.
Inger öhlund and colleagues in a study of Swedish infants between 6 and 12
month old, published in 2008, found that total fat intake complied with the
Nordic recommendations, but polyunsaturated fatty acids of 5.6% was to low
and saturated fatty acids with 15,1% of total energy was too high. The
authors found that high polyunsaturated fatty acids intake was associated with
lower total serum cholesterol, lower low-density-lipoprotein cholesterol and
apolipoprotein B in girls but not in boys.
The authors stress that higher polyunsaturated fatty acids and lower saturated
fatty acids intakes may reduce total cholesterol and lower
low-density-lipoprotein cholesterol LDL-C early in life. The authors recommend to
focus on fat quality rather than on quantity to lower serum lipid concentrations
in early childhood. 
The Euro-Growth Study of milk feeding (Freeman, van't Hof, Haschke 2000) found that at the age of I month, 52% of the infants were exclusively breast fed and 26% were exclusively formula fed.
At the age of 9 months, 18% of infants were fed only cow's milk.
At the ages of 3, 4, and 5 months, 50%, 67%, and 95% of infants were fed solid foods, respectively.
The study found high rates of breast-feeding initiation are found in Umea, Sweden, and in Athens, Greece; and low rates in Dublin, Ireland, in Toulouse, France, and in Glasgow, United Kingdom. The authors concluded that the use of cow's milk as the main milk drink before the age of 12 months is still common in certain European centres. 
Claire C. Stocker and colleagues (2007) report that supplementing infant rats' diets with the hormone leptin resulted in adult animals that did not fat or develop diabetes, even when fed a high-fat diet. The researchers concluded that leptin levels during pregnancy and lactation can affect the development of energy balance regulatory systems in their offspring.
Stocker points out that the absence of leptin is known to disrupt the development of energy balance regulatory mechanisms. Adding leptin to infant formulas could turn baby foods more similar to the composition of mother milk similar which contains leptin.
Breastfeeding may often not be possible because of health situation of the mother or for comodity reasons. Thus well balanced infant formulas replicating the healthy profile of breast milk as far as possible are essential for the fist months of life. This article started a discussion on leptin.
Leptin in new UK baby food 
In UK new infant formula with leptin will be lauched in late 2007 with the intention to protect from obesity and diabetes into adulthood. Leptin is present in milk but not in infant formulas. Adding leptin could restore natural composition of baby food. 
Leptin is a hormone that plays a key role in regulating energy intake and energy expenditure, including the regulation (decrease)of appetite and metabolism.Leptin is produced by adipose tissue and interacts with six types of receptor (LepRa-LepRf). LepRb is the only receptor isoform that contains active intracellular signaling domains.
This receptor is present in a number of hypothalamic nuclei, where it exerts its effects. Importantly, leptin binds to the Ventral Medial nucleus of the hypothalamjus, known as the satiety center. Binding of leptin to this nucleus signals to the brain that the body has had enough to eat - a sensation of satiety. 
Leptin is an appetite-suppressing hormone secreted by fat tissue. It was
proposed to treat obesity, however, obese persons were found to develop leptin
Umut Ozcan and colleagues 2009 found that elevated leptin secretion increased
the stress on a part of the brain, the endoplasmic reticulum, which assembles
proteins and folds them into their appropriate configurations. Under stress
the endoplasmic reticulum produces unfolded protein in the hypothalamus of
obese mice resulting in results in severe leptin resistance and obesity.
The stress triggers the production of unfolded proteins, that tries to relieve
the stress by increasing the level of molecular "chaperones," which assist in
protein folding, and by blocking more proteins from coming in.
The authors suggest a new treatment of obesity with chemical chaperones,
4-phenyl butyric acid (PBA), and tauroursodeoxycholic acid (TUDCA), which were
found to decrease endoplasmic reticulum stress and act as leptin-sensitizing
Absorption of fat molecules
Xenical (orlistat), Roche's (Basel, Switzerland) drug that blocks the breakdown and absorption of about 30% of dietary fats.
Studies on a fatty acid transporter (FATP4) which blocks the uptake of fatty acids which result from the digestion of fat may replace Xenical.
Thyreoid hormones stimulating thermogenesis to burn off excessive caused loss of bone calcium.
Increasing the expression of uncoupling proteins (UCPs) to create heat and thus reduce risk of obesity and agonists of the beta3-adrenergic receptor which also targets the energy output, are being studied.
Feeling of satiety
Peptides produced by the gastrointestinal system and pancreas such as cholecystokinin (CCK), and others include neuromedin B, gastrin-releasing peptide, and enterostatin naturally regulate peripheral feelings of satiety and the amount of food consumed.
Centrally acting appetite suppressants in weight-reducing drugs such as Redux (dexfenfluramine) and fenfluramine in combination with phentermine (acts as a noradrenaline reuptake inhibitor) in the fen-phen diet drug were approved by FDA in 1996 and withdrawn in the same year because of link to heart valve damage. 
Dexfenfluramine boosted serotonin levels by stimulating its release and inhibited its reuptake. The American Home Products (AHP) company is being sued for withholding and concealing informations on the safety of the drug. The company still researches on serotonergic control systems, however, it concentrates on mice studies targeting the 5-HT2c subtype of receptor 5-HT.
Leptin, a fat-regulating hormone
Jeffrey Friedman and his team (2002) discovered the "ob" gene, which underlies the gross obesity in the ob/ob strain of mice. Injecting leptin back into the ob/ob mice appetites were reduced and the excess weight was lost. 
Jeff Flier, an obesity researcher at Harvard's Beth Israel Deaconess stressed the fact that high levels of endogenous leptin in obese people had been found, suggesting that sensitivity to leptin is lost and cannot be restored by further elevation of the compound. The company Amgen is still working on new formulations on the product. It has been used successfully to treat a handful of severely obese children who have an inherited deficiency in the hormone.
Researchers now suspect that obese people appear to be resistant to leptin because the hormone is not transported into the brain.
Leptin is produced by fat cells, circulating in the blood to the hypothalamus where it works through a number of nuclei and pathways to reset the body's weight controller. As fat levels increase, leptin levels rise, triggering a reduction of food intake and increasing metabolism.
Leptin inhibits the release of neuropeptide Y (NPY), a small protein that increases appetite.
Leptin is related to the alfa-melanocyte-stimulating hormone (alfa-MSH), which is actually a fragment of the precursor protein POMC.alfa-MSH acts through the MCR-4 receptor to reduce appetite.
Leptin increases the production of the SOCS-3 (suppressor of cytokine signaling-3) protein, which terminates its activity at the leptin receptor. The SOCS-3 a regulator of the leptin signaling pathways in healthy individuals, it is overactive in obese patients.
Researchers of Johns Hopkins University discovered that malonyl coenzyme A inhibits NPY independently of leptin, decreasing appetite in mice and might lead to eight loss in humans.
Ciliary neurotrophic factor (CNTF)
George Yancopoulos of Regeneron tested Axokine (ciliary neurotrophic factor, CNTF) as a treatment of a disease noted that the drug used the same signaling pathway as leptin with the effect of weight reduction. There are hope that the drug has better effects compared with leptin, but it must be injected, because it is not stable by oral intake.
Fatty acid synthase inhibitors (cerulenin and compound C75)
Francis P. Kuhajda and colleagues (2000) identified a link between anabolic energy metabolism and appetite control. According to the authors treating mice with fatty acid synthase (FAS) inhibitors (cerulenin and a synthetic compound C75) inhibited feeding and caused a dramatic weight loss. C75 inhibited expression of the prophagic signal neuropeptide Y in the hypothalamus and acted in a leptin-independent manner that appears to be mediated by malonyl-coenzyme A. They conclude that FAS may become important in feeding regulation.
Fatty acid synthase (FAS) and carnitine palmitoyltransferase-1 
Gabriele V. Ronnett and colleaugues (2006) say that fatty acid synthase (FAS) catalyzes the synthesis of long-chain fatty acids, whereas the breakdown of fatty acids by beta-oxidation is regulated by carnitine palmitoyltransferase-1, the rate-limiting enzyme for the entry of fatty acids into the mitochondria for oxidation.
Studies indicate that inhibition of FAS or stimulation of carnitine palmitoyltransferase-1 using cerulenin or synthetic FAS inhibitors reduces food intake with resulting weight loss. compounds also increase energy consumption. The authors say that at least part of C75's effects is mediated by modulation of adenosine monophosphate-activated protein kinase, a member of an energy-sensing kinase family, and conclude that these effects could be useful in obesity therapy.
Leptin and melanocortin activity on the hypothalamus 
Shimizu and colleagues (2007) note that the brain hypothalamus coordinates extra-hypothalamic regions to maintain energy homeostasis through the regulation of food intake and energy expenditure. According to these authors leptin and pro-opiomelanocortin (POMC)-derived alfa-melanocyte-stimulating hormone are key anorectic molecules, and the leptin receptor and POMC gene are both expressed in the hypothalamic arcuate nucleus. Data support the concept of a leptin-independent melanocortin signaling system in the regulation of energy homeostasis.
The position of the charity Weight Concern 
According to Dr. Ian Campbell, medical director of the charity Weight Concern leptin has proved to be a great disappointment, and most of us have plenty and true deficiencies are rare. Obese people tend to have higher than normal levels. 
Rzehak and colleagues 2009 analysed differences of body mass index (BMI) of infants fed with partially hydrolysed whey (pHF-W), extensively hydrolysed whey (eHF-W), extensively hydrolysed casein (eHF-C), or cow-milk formula (CMF) and infants exclusively breastfed.
The authors report no differences in BMI in all groups, except the extensively hydrolysed casein (eHF-C) group,which presented a lower weight gain in the first year of life, but not later with no long-term consequences of different formulas on BMI. 
Mennella and colleagues 2011 assessed differences in feeding behaviour and growth of infants of ages 0.5 to 7.5 months, fed with an extensively protein hydrolysate formula compared with infants fed with cow-milk formula. Anthropometric Z-scores were calculated using the World Health Organization growth standards. 
Infants fed with protein hydrolysate formula presented lower weight-for-length z scores, slower weight gain velocity, and consumed less formula to satiation than infants fed with cow-milk formula.
The authors call for more studies on longer-term effects of hydrolysed protein diets focusing on later development of obesity, diabetes, other diseases, long-term consequences of the early growth differences associated with infant formulas, and how it differs from breastfeeding. 
Acccording to Andres and colleagues 2007, rotavirus infections cause acute
gastroenteritis in children and are responsible forfive percent of all child
deaths globally. Infection affects almost all children within their first 5
years of life. Soy-based infant formula, containing high levels of isoflavones
were found to have antiviral activity on numerous viruses. The authors found
that genistin was responsible for the inhibition of rotavirus activity of the
isoflavones from soy.
The authors suggest that the modulation of isoflavone composition and
concentration of infant formulas may reduce the severity of rotavirus
infection in human and production animals. 
Soya formula for infants should only be administered on doctor's advice
According to the German Federal Institute for Risk assessment (BfA) If a mother
is unable to breastfeed her baby, she can fall back on infant formula from the
drug store or supermarket. However, soybeans contain high concentrations of
isoflavones genistein and daidzein.
Besides isoflavones, soy formula may also contain phytate. The natural plant
component can influence the intake of minerals and trace elements.
Furthermore, soybeans may also contain higher amounts of the plant component,
phytate. Professor Dr. Dr. Andreas Hensel, President of the Federal Institute
for Risk Assessment (BfR), comments, "Infant formula and follow-up formula
made from soy protein should only be administered on medical grounds and then
only under medical supervision."
The Health Committee of New Zealand recommends that the current mandatory
label on soy-based infant formula should be amended to read: "Breastmilk is
best for babies. Soy-based formulas have a high phytoestrogen content, which
may pose a risk for the long-term reproductive health of infants. Before you
decide to use this product, consult your doctor or nurse for advice."
Botulism in infants 6 weeks to 1 year of age was first recognized as a
distinct clinical entity in 1976. This form of botulism results from growth
and toxin production by C. botulinum within the intestinal tract of infants
rather than from ingestion of a food with preformed toxin. It is usually caused
by C. botulinum types A or B, but a few cases have been caused by other
types.botulism has been diagnosed in most U.S. states and in every populated
continent except Africa.
Honey, a known source of C. botulinum spores, has been implicated in some
cases of infant botulism. In studies of honey, up to 13% of the test samples
contained low numbers of C. botulinum spores.Heat treatment is not sufficient
to destroy C. botulinum spores, but the high sugar content of the honey
prevents the spores from germinating. Normal adults are not at risk of
botulism from eating honey; however, the gastrointestinal tracts of young
infants (under one year of age) may promote spore germination.
For this reason, the FDA, the Centers for Disease Control and Prevention
(CDC), and the American Academy of Pediatrics recommend not feeding honey to
infants under one year old. 
According to the Federal Institute for Risk Assessment (BfR) the substance
3-monochloropropane-1,2-diol (3-MCPD) may be formed when fat-containing foods
that also contain salt are exposed to high temperatures during production. It
has been detected in numerous heated foods, for instance in dark brown toast,
infant formula and follow-up formula. During the production of fats and oils,
3-MCPD fatty acid esters may be formed from 3-monochloropropane-1,2-diol when
the fats and oils are heated to high temperatures.
The BfR recommends that concerted action be taken to lower the levels of
3-MCPD esters in infant formula and follow-up formula, contain varying
amounts of dried powder and water. The Institute recommends that mothers who
are unable to breastfeed their infants and give them infant formula should
continue to do so. Infants who are not breastfed there is no alternative to
formula and follow-up formula. Mothers should not switch to cow, goat or horse
milk either as they do not contain some of the essential nutrients that infants need.
Detected levels of 3-MCPD fatty acid esters
The BfR found that the amounts of 3-MCPD fatty acid esters detected in edible
oils and fats were in the four to five digit microgram range. The highest
level of 11,206 micrograms per kilogram (microg/kg) was found in deep-frying
fat. In the infant formula and follow-up formula examined the highest level
identified was 4,196 microg/kg in the fat content. For this food it amounts to
around 25 percent of the dried powder.
The BfR stresses that it is unknown whether 3-MCPD fatty acid esters have the
same toxic properties as free 3-MCPD. No data are available but it cannot be
ruled out that free 3-MCPD is formed from most of the fatty acid esters during
According to the BfR men who consume 100 g of vegetable margarine with the
highest detected level of 3-MCPD fatty acid esters daily would exceed the TDI
five-fold, assuming that 3-MCPD fatty acid esters are fully converted into
free 3-MCPD. Following tis assumption, intakes of formula and follow-up
formula, infants would exceed the TDI three to twenty-fold.
Risk for infants and consumers
According to the BFR there are many uncertanties of a risk assessment. However,
assuming that toxicological effects of 3-MCPD on animals can be translated to
humans or that there is large scale conversion of 3-MCPD fatty acid esters into
3-monochloropropane-1,2-diol, then the expected long-term exceeding of the TDI is
not acceptable in the opinion of BfR particularly as children and adults ingest
3-MCPD from other sources, too. Any short-term exceeding of the TDI value would,
by contrast, not present a safety concern.
BFR: Infant Nutrition.
FSA: Eat well, be well: Weaning your baby.
Kiefte de Jong JC, de Vries JH, Franco OH, Jaddoe VWV, Hofman A, Raat H, de Jongste JC, and Moll HA.
Fish consumption in infancy and asthma-like symptoms at preschool age.
peds, 0875, 2012.
COMMISSION DIRECTIVE 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes.
European infant formula and follow-on formula Regulation Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC Text with EEA relevance.
Baby Milk Action: New UK formula labels lack correct information - calls for better warnings and instructions.
IDFA Newsroom: IDFA's action to protect the continued supply of baby milk formula.
Food Standards Agency: Judicial review of infant formula regulations.
The 26. Session of the Codex Committee on Nutrition and Foods for Special Dietary Uses. ALINORM 05/28/26.
The 27.Session of the Codex Committee on Nutrition and Foods for Special Dietary Uses. 21 - 25 November 2005 ALINORM 06/29/26.
The 28.Session of the Codex Committee on Nutrition and Foods for Special Dietary Uses. 30 October - 3 November 2006. ALINORM 07/30/26-Rev.
Advisory Lists of Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children (CAC/GL 10-1979.
Recommended International Code of Practice - General Principles of Food Hygiene (CAC/RCP 1 1969, Rev. 3 - 1997).
Recommended International Code of Hygienic Practice for Foods for Infants and Children (CAC/RCP 21-1979).
Principles for the Establishment and Application of Microbiological Criteria for Foods (CAC/GL 21-1997).
Codex General Standard for the Labelling of Prepackaged Foods (CODEX STAN 1-1985 (Rev. 1-1991).
Codex Guidelines on Nutrition Labelling (CAC/GL 2-1985 (Rev.1-1993).
Guidelines for Use of Nutrition and Health Claims.
Lozoff, Betsy; De Andraca, Isidora; Castillo, Marcela; Smith, Julia B.; Walter, Tomas; Pino, Paulina: Behavioral and Developmental Effects of Preventing Iron-Deficiency Anemia in Healthy Full-Term Infants. Pediatrics Vol. 112 No. 4 October 2003, pp. 846-854.
Olney, Deanna K.; Pollitt, Ernesto; Kariger, Patricia K.; Khalfan, Sabra S.; Ali, Nadra S.; Tielsch, James M.; Sazawal, Sunil; Black, Robert; Allen, Lindsay H.; Stoltzfus, Rebecca J.: Combined Iron and Folic Acid Supplementation with or without Zinc Reduces Time to Walking Unassisted among Zanzibari Infants 5- to 11-mo old. J. Nutr., September 1, 2006; 136(9): 2427 - 2434.
Wasantwisut, Emorn; Winichagoon, Pattanee; Chitchumroonchokchai, Chureeporn; Yamborisut, Uruwan; Boonpraderm, Atitada; Pongcharoen, Tippawan; Sranacharoenpong, Kitti; Russameesopaphorn, Wanphen: Iron and Zinc Supplementation Improved Iron and Zinc Status, but Not Physical Growth, of Apparently Healthy, Breast-Fed Infants in Rural Communities of Northeast Thailand J. Nutr., September 1, 2006; 136(9): 2405 - 2411.
Khulan B, Cooper WN, Skinner BM, Bauer J, Owens S, Prentice AM, Belteki G, Constncia M, Dunger D, and Affara NA.
Periconceptional maternal micronutrient supplementation is associated with widespread gender related changes in the epigenome: a study of a unique resource in the gambia.
Hum Mol Genet, 2 2012.
Cooper WN, Khulan B, Owens S, Elks CE, Seidel V, Prentice AM, Belteki G, Ong KK, Affara NA, Constncia M, and Dunger DB.
Dna methylation profiling at imprinted loci after periconceptional micronutrient supplementation in humans: results of a pilot randomized controlled trial.
FASEB J, 1 2012.
Conference on "multidisciplinary approaches to nutritional problems". postgraduate symposium. exploiting dietary supplementation trials to assess the impact of the prenatal environment on cvd risk.
Proc Nutr Soc, 68(1):78-88, 2 2009.
Hawkesworth S, Walker CG, Sawo Y, Fulford AJ, Jarjou LM, Goldberg GR, Prentice A, Prentice AM, and Moore SE.
Nutritional supplementation during pregnancy and offspring cardiovascular disease risk in the gambia.
Am J Clin Nutr, 94, 12 2011.
Tompkins, Thomas A.; Renard, Nadine E.; Kiuchi, Akira: Clinical Evaluation of the Bioavailability of Zinc-enriched Yeast and Zinc Gluconate in Healthy Volunteers. Biological Trace Element Researche , Humana Press, (Humana Press). Volume 120, Numbers 1-3 / December 2007 pp 28-35 (8)doi: 10.1007/s12011-007-0072-2.
Vinson, Joe A.; Tompkins, Thomas A. Agbor, Gabriel A.: Comparative Bioavailability of Mineral-enriched Gluconates and Yeast in Rat Liver After Depletion-Repletion Feeding. Biological Trace Element Researche , Humana Press. Volume 118, Number 2 / September, 2007 104-110 (7).
öhlund, Inger; Lind, Torbjörn; Hörnell, Agneta; Hernell, Olle: Predictors of iron status in well-nourished 4-y-old children. American Journal of Clinical Nutrition, Vol. 87, No. 4, 839-845, April 2008.
Lozoff, B.; Clark, K.M.; Jing, Y.; Armony-Sivan R.; Angelilli, M.L.; Jacobson, S.W.: Dose-response relationships between iron deficiency with or without anemia and infant social-emotional behavior. 2008 May;152(5):696-702, 702.31-3. Epub 2007 Nov 19.
Lozoff, Betsy; Castillo, Marcela; Smith, Julia B.: Poorer developmental outcome at 10 years with 12 mg/L iron-fortified formula in infancy PAS Meeting 2008; Abstract 5340.2.
EU Commission: Commission Directive of 14 May 1991 on infant formulae and follow-on formulae (91/321/EEC).
Shafir T.; Angulo-Barroso, R.; Jing Y.; Angelilli, M.L.; Jacobson, S.W.; Lozoff, B.: Iron deficiency and infant motor development. Early Hum Dev, 2008 Feb 11.
Koletzko, Berthold; Baker, Susan; Cleghorn, Geoff; Fagundes Neto, Ulysses; Gopalan, Sarath; Hernell, Olle; Hock, Quak Seng; Jirapinyo, Pipop; Lonnerdal, Bo;Pencharz, Paul; Pzyrembel, Hildegard; Ramirez-Mayans, Jaime; Shamir, Raanan; Turck, Dominique; Yamashiro, Yuichiro and Zong-Yi, Ding: Global Standard for the Composition of Infant Formula: Recommendations of an ESPGHAN Coordinated International Expert Group. J Pediatr Gastroenterol Nutr 2005; 41: 58-599.
Domellöf, Magnus; Agostoni, Carlo: Infant Formulae: From ESPGAN Recommendations Towards ESPGHAN-coordinated Global Standards. Journal of Pediatric Gastroenterology and Nutrition 41:580-583 November 2005.
Agostoni,Carlo, Goulet, Olivier; Kolacek, Sanja; Koletzko, Berthold; Moreno, Luis; Puntis, John; Rigo, Jacques; Shamir, Raanan; Szajewska, Hania; Turck, Dominique; ESPGHAN Committee on Nutrition: Fermented Infant Formulae Without Live Bacteria. J Peditr Gastroenterol Nutr March 2007, 44(3) 392-397.
öhlund, I.; Hörnell, A.; Lind, T.; Hernell, O.: Dietary fat in infancy should be more focused on quality than on quantity: European Journal of Clinical Nutrition (2008) 62, 1058-1064; doi:10.1038/sj.ejcn.1602824.
Freeman, V.; van't Hof, M.; Haschke, F.: Patterns of milk and food intake in infants from birth to age 36 months: the Euro-growth study. J Pediatr Gastroenterol Nutr. 2000; 31 Suppl 1:S76-85.
Stocker, Claire J.; Wargent, Ed; O'Dowd, Jackeline; Cornick,Claire; Speakman, John R.; Arch, Jonathan R.S.; Cawthorne, Michael A.: Prevention of diet-induced obesity and impaired glucose tolerance in rats following administration of leptin to their mothers. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology doi: 10.1152/ajpregu.00676.2006.
The Society of Chemical Industry. New formula for fit future. Baby food offering lifetime protection against obesity could be in the supermarket soon, Lisa Melton. Chemistry & Industry magazine.
Lale Ozcan, Ayse Seda Ergin, Allen Lu, Jason Chung, Sumit Sarkar, Duyu Nie, Martin G. Myers, Umut Ozcan: Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin Resistance. Cell Metabolism, Volume 9, Issue 1, 35-51, 7 January 2009.
Alan Dove: Biotech weighs up the options in obesity.Nature Biotechnology 19, 25 - 28 (2001) doi:10.1038/83465.
CDC: Cardiac Valvulopathy Associated with Exposure to Fenfluramine or Dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations, November 1997. November 14, 1997 / Vol. 46 / No. 45.
Zhang,Yiying; Proenca, Ricardo; Maffei, Margherita; Barone, Marisa; Leopold, Lori and. Friedman, Jeffrey M.: Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425 - 432 (01 December 2002); doi:10.1038/372425a0.
Loftus, Thomas M.; Joworski, Donna M.; Frehywot Gojeb L; Townsend, Craig A.; Ronnett, Gabriele V.; Lane, Daniel M.; Kuhajda, Francis P.: Reduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors. Science 30 June 2000: Vol. 288. no. 5475, pp. 2379 - 2381 DOI: 10.1126/science.288.5475.2379.
Ronnett, Gabriele V.; Kleman, Amy M. ; Kim, Eun-Kyoung; Landree Leslie E. and Tu, Yajun: Fatty Acid Metabolism, the Central Nervous System, and Feeding. Obesity 14:201S -207S (2006).
Shimizu, Hiroyuki; Inoue, Kinji and Mori, Masatomo: The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure. J. Endocrinol.2007 193, 1-9 DOI: 10.1677/JOE-06-0144.
BBC News: Fat-fighting baby milk criticised. Sunday, 22 April 2007, 23:11 GMT 00:11 UK.
Rzehak P, Sausenthaler S, Koletzko S, Reinhardt D, von Berg A, Krämer U, Berdel D, Bollrath C, Grübl A, Bauer CP, Wichmann HE, Heinrich J, and German Infant Nutritional Intervention Study Group:.
Short- and long-term effects of feeding hydrolysed protein infant formulas on growth at < or = 6 y of age. results from the german infant nutritional intervention study.
Am J Clin Nutr., 89:1846-56, 6 2009.
Mennella JA, Ventura AK, and Beauchamp GK.
Differential growth patterns among healthy infants fed protein hydrolysate or cow-milk formulas.
Pediatrics, 127:110-8, 1 2011.
The who child growth standards.
Andres, Aline; Donovan, Sharon M.; Kuhlenschmidt, Theresa B.; Kuhlenschmidt, Mark S.: Isoflavones at Concentrations Present in Soy Infant Formula Inhibit Rotavirus Infection in Vitro J. Nutr. 2007 137: 2068-2073.
BfR: Infant formula made from soy protein is no substitute for cow's milk products. 19.11.2007.
Report of the New Zealand House of Representatives Health Committee on Petition 2005/123 of Valerie Ann James and 214 others. Heard on 17 October 2007.
FDA : Clostridium botulinum. Bacteriological Analytical Manual Online. Chapter 17.
BFR: Frequently Asked Questions about 3-monochloropropane-1,2-diol (3-MCPD).
See also: Related OurFood News
Copyright © 1998 - 2013 by K. H. Wilm - Impressum